Onconetix, Inc. Files 8-K
Ticker: ONCO · Form: 8-K · Filed: Sep 5, 2024 · CIK: 1782107
Sentiment: neutral
Topics: 8-K, filing, corporate-actions
Related Tickers: ONCO
TL;DR
ONCO filed an 8-K on 9/4 - could be big news, check it out.
AI Summary
Onconetix, Inc. filed an 8-K on September 4, 2024, reporting other events and financial statements. The company, formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc., is incorporated in Delaware and headquartered in Cincinnati, Ohio. The filing does not contain specific financial figures or details about the 'other events'.
Why It Matters
This 8-K filing indicates that Onconetix, Inc. has reported significant events and financial statements, which could impact investor understanding of the company's current status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting form without specific material disclosures that would immediately indicate high risk.
Key Players & Entities
- Onconetix, Inc. (company) — Registrant
- Blue Water Biotech, Inc. (company) — Former company name
- Blue Water Vaccines Inc. (company) — Former company name
- September 4, 2024 (date) — Date of earliest event reported
- 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio 45202 (address) — Principal executive offices
FAQ
What specific 'Other Events' are being reported by Onconetix, Inc. in this 8-K filing?
The provided text of the 8-K filing does not specify the details of the 'Other Events' being reported.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 4, 2024.
What were the previous names of Onconetix, Inc.?
Onconetix, Inc. was formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc.
Where are Onconetix, Inc.'s principal executive offices located?
Onconetix, Inc.'s principal executive offices are located at 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio 45202.
What is the Standard Industrial Classification (SIC) code for Onconetix, Inc.?
The Standard Industrial Classification (SIC) code for Onconetix, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 774 words · 3 min read · ~3 pages · Grade level 14.1 · Accepted 2024-09-04 19:55:41
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share ONCO The Nasdaq Stock Mar
- $5 million — Stock to be issued by the Company in a $5 million private placement financing of units (t
Filing Documents
- ea0213522-8k_onconetix.htm (8-K) — 25KB
- ea021352201ex99-1_onconetix.htm (EX-99.1) — 320KB
- 0001213900-24-075697.txt ( ) — 535KB
- onco-20240904.xsd (EX-101.SCH) — 3KB
- onco-20240904_lab.xml (EX-101.LAB) — 33KB
- onco-20240904_pre.xml (EX-101.PRE) — 22KB
- ea0213522-8k_onconetix_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. As previously disclosed, Onconetix, Inc. (the " Company ") is holding an annual meeting of stockholders on September 5, 2024 (the " Annual Meeting "), at which stockholders will vote on, among other things, in accordance with Nasdaq Listing Rule 5635, the issuance of: (i) 269,672,900 shares of Company common stock, par value $0.00001 per share (" Common Stock ") to be issued upon conversion of the Company's Series B Preferred Stock, par value $0.00001 per share (" Series B Preferred Stock "), (ii) such number of shares of Common Stock to be issued by the Company in a $5 million private placement financing of units (the " PMX Financing "), which shall initially include 20,000,000 shares of Common Stock and up to 6,000,000 shares of Common Stock underlying warrants included in the units, subject to adjustment, plus such additional number of shares of Common Stock to be issuable upon the satisfaction of certain price protection conditions, and (iii) the assumption and conversion of outstanding stock options of Proteomedix AG (" Proteomedix ") in accordance with the terms of the Share Exchange Agreement dated December 15, 2023 by and among the Company and Proteomedix AG, among other parties (the " Share Exchange Agreement "). If approved at the Annual Meeting, the conversion of the Series B Preferred Stock will constitute a business combination that results in a "Change of Control" pursuant to Nasdaq Listing Rule 5110(a), and, as a result, the Company will be required to satisfy all of Nasdaq's initial listing criteria and to complete Nasdaq's initial listing process prior to shareholder approval of the conversion of the Series B Preferred Stock, or other material changes triggering a change of control. In connection with the Company's initial listing application to Nasdaq, the Company is filing pro forma financial statements (the " Pro Formas ") that give effect to (i) the issuance 269,672,900 shares of Company common stock to be issued upon
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Unaudited pro-forma consolidated financial information of the Company and Proteomedix for the period ended June 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Onconetix, Inc. September 4, 2024 By: /s/ Karina Fedasz Name: Karina Fedasz Title: Interim Chief Financial Officer 2